The Company, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The Company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The Company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
HISTORY
2017 - The Company is a holding company incorporated in British Virgin Islands on July 4, 2017. The Company is headquartered in Taizhou, China.
- On July 21, 2017, the Company wholly owned subsidiary China SXT Group Limited (“SXT HK”) was incorporated in Hong Kong.
2019 On January 3, 2019, The Company s ordinary shares commenced trading on the Nasdaq Capital Market under the symbol of “SXTC.”
Headquarters
178 Taidong Rd North
Taizhou; Zhejiang;
Postal Code: 225300
Contact Details: Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Website: http://www.sxtchina.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service